Global Dendritic Cell Cancer Vaccine Market-Industry Analysis, Growth, Segmentation and Forecast-2019-2027

The global Dendritic Cell Cancer vaccine market was valued at $XX Mn in 2019 and is expected to reach $XX Mn in 2027 at a CAGR of XX%.

Global Dendritic Cell Cancer Vaccine Market Introduction and Overview

The past decade has seen tremendous developments and breakthroughs in novel cancer therapies. Emerging new techniques, which target specific cancer cells and their intrinsic pathways are a boon for cancer patients. Current immunotherapies and precision medicines are boosting the cancer vaccine market growth. Dendritic cells (DCs) are specialized immune cells that play a vital role in promoting an immune response against foreign pathogens. They are effective inhibitors of the naïve T-cell responses. The Dendritic cell vaccine immunotherapy has its applications involved in major treatments and thus has a wider acceptance across the globe. The technological and innovative advancements in this field are a new ray of hope for the cancer mortality rate to decline. Increasing novel research centers, understanding of biological mechanisms of the human immune system and cancer, and developing advanced techniques are estimated to create promising opportunities for researchers, physicians, and the market stakeholders. In addition to this, the rising prevalence of cancer cases, increased revenue for healthcare sectors and awareness about the dendritic cell cancer vaccine immunotherapy are also aiding the market growth. The dendritic cell vaccine immunotherapy has revolutionized the market with its exciting and novel range of techniques. In comparison with chemotherapy and radiation therapy, this technique has almost no side effects which are elevating the market towards the north. The Dendritic Cell cancer vaccine market is achieving heights due to the smart mechanism of action of dendritic cells on cancer cells. Also, increased access to patient data due to advancements in AI is bringing in investments for this market. More than $1.5 Bn has already been invested in this area over the last 5 years.

Global Dendritic Cell Cancer Vaccine Market Segment Analysis

The product type segment for the dendritic cell cancer vaccine is expected to grow at a faster pace, the reason being the demand for Sipuleucel (Provenge) vaccine. Provenge was the first therapeutic vaccine approved by FDA. It was the first marketed vaccine that generated high revenues for the pharmaceutical companies. The market for this is expected to grow from $XX Mn in 2019 to $XX Mn in 2027. It targets prostate cancer by utilizing the patient’s own immune system. The rising cases of prostate cancer are expected to grow the market. Global Dendritic Cell Cancer Vaccine Market To know about the Research Methodology :- Request Free Sample Report

Global Dendritic Cell Cancer Vaccine Market Segmentation

The Global Dendritic Cell Cancer vaccine Market is segmented-

Global Dendritic Cell Cancer Vaccine Market, By Product Type

• CreaVax • Sipuleucel-T (Provenge) • Others

Global Dendritic Cell Cancer Vaccine Market, By End-user

• Paediatrics • Adults

Scope of the report: Inquire before buying

Global Dendritic Cell Cancer Vaccine Market Regional Insights

Global Dendritic Cell Cancer Vaccine Market1 Based on the regional analysis, North America is estimated to dominate the dendritic cell cancer vaccine market in the forecast period. The first FDA-approved vaccine Provenge has driven the market here, from $XX Mn in 2019 and is expected to reach $XX Mn during the forecast period. The production of vaccines globally is expanding the market size to a greater extent. In the APAC region, South Africa and India is developing products for other indications. CreaVax of South Africa for prostate cancer and Apceden in India for the solid tumor are developed, growing the market revenue in the APAC region. In addition to this, Vaccell in Japan, TAP Cells in Chile, MelCancerVac in North America, and Rocapuldencel-T in the US are the vaccines which have entered different phases of clinical trials. These vaccines are expected to be approved soon, enhancing the growth of dendritic cell cancer vaccine market globally.

Key Players operating in the Global Dendritic Cell Cancer Vaccine Market-

• 3M Company • Batavia Bioservices • CiMaas • Activartis • Dendreon • Merck KGaA • GlaxoSmithKline plc • Northwest Bio therapeutics • Tella Incorporation • Creagene • Immunocellular Therapeutics • Medigene AG • HOOKPIA Pharma Inc • PDC Line Pharma • Kiromic • Immunicum • DCPrime • DanDrit Biotech • Elios Therapeutics • Bellicium Pharmaceuticals • SOTIO • Theravectys • Vaxil Bio therapeutics • Argos Therapeutics

Global Dendritic Cell Cancer Vaccine Market Competitive Landscape

As per the news released on January 9 2021, CiMaas has received an important stimulus from the Netherlands Enterprise Agency (RVO) for the development of a therapeutic dendritic cell vaccine against lung cancer. It has been approved with a loan of € 2.4 million. According to CiMaas, the loan and previous contributions by investors are enough for performing clinical trials up to 2 phases. The objective of the report is to present a comprehensive analysis of the Global Dendritic Cell Cancer Vaccine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Dendritic Cell Cancer Vaccine Market dynamics, structure by analysing the market segments and project the Global Dendritic Cell Cancer Vaccine Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Dendritic Cell Cancer Vaccine Market make the report investor’s guide.
Global Dendritic Cell Cancer Vaccine Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: DENDRITIC CELL CANCER VACCINE Market Size, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global DENDRITIC CELL CANCER VACCINE Market Analysis and Forecast 6.1. DENDRITIC CELL CANCER VACCINE Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global DENDRITIC CELL CANCER VACCINE Market Analysis and Forecast, By Product Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. DENDRITIC CELL CANCER VACCINE Market Value Share Analysis, By Product Type 7.4. DENDRITIC CELL CANCER VACCINE Market Size (US$ Mn) Forecast, By Product Type 7.5. DENDRITIC CELL CANCER VACCINE Market Analysis, By Product Type 7.6. DENDRITIC CELL CANCER VACCINE Market Attractiveness Analysis, By Product Type 8. Global DENDRITIC CELL CANCER VACCINE Market Analysis and Forecast, By End-user 8.1. Introduction and Definition 8.2. Key Findings 8.3. DENDRITIC CELL CANCER VACCINE Market Value Share Analysis, By End-user 8.4. DENDRITIC CELL CANCER VACCINE Market Size (US$ Mn) Forecast, By End-user 8.5. DENDRITIC CELL CANCER VACCINE Market Analysis, By End-user 8.6. DENDRITIC CELL CANCER VACCINE Market Attractiveness Analysis, By End-user 9. Global DENDRITIC CELL CANCER VACCINE Market Analysis, By Region 9.1. DENDRITIC CELL CANCER VACCINE Market Value Share Analysis, By Region 9.2. DENDRITIC CELL CANCER VACCINE Market Size (US$ Mn) Forecast, By Region 9.3. DENDRITIC CELL CANCER VACCINE Market Attractiveness Analysis, By Region 10. North America DENDRITIC CELL CANCER VACCINE Market Analysis 10.1. Key Findings 10.2. North America DENDRITIC CELL CANCER VACCINE Market Overview 10.3. North America DENDRITIC CELL CANCER VACCINE Market Value Share Analysis, By Product Type 10.4. North America DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 10.4.1. CreaVax 10.4.2. Sipuleucel-T (Provenge) 10.4.3. Others 10.5. North America DENDRITIC CELL CANCER VACCINE Market Value Share Analysis, By End-user 10.6. North America DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 10.6.1. Paediatrics 10.6.2. Adults 10.7. North America DENDRITIC CELL CANCER VACCINE Market Value Share Analysis, By Country 10.8. North America DENDRITIC CELL CANCER VACCINE Market Forecast, By Country 10.8.1. U.S. 10.8.2. Canada 10.8.3. Mexico 10.9. North America DENDRITIC CELL CANCER VACCINE Market Analysis, By Country 10.10. U.S. DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 10.10.1. CreaVax 10.10.2. Sipuleucel-T (Provenge) 10.10.3. Others 10.11. U.S. DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 10.11.1. Paediatrics 10.11.2. Adults 10.12. Canada DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 10.12.1. CreaVax 10.12.2. Sipuleucel-T (Provenge) 10.12.3. Others 10.13. Canada DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 10.13.1. Paediatrics 10.13.2. Adults 10.14. Mexico DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 10.14.1. CreaVax 10.14.2. Sipuleucel-T (Provenge) 10.14.3. Others 10.15. Mexico DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 10.15.1. Paediatrics 10.15.2. Adults 10.16. North America DENDRITIC CELL CANCER VACCINE Market Attractiveness Analysis 10.16.1. By Product Type 10.16.2. By End-user 10.17. PEST Analysis 10.18. Key Trends 10.19. Key Developments 11. Europe DENDRITIC CELL CANCER VACCINE Market Analysis 11.1. Key Findings 11.2. Europe DENDRITIC CELL CANCER VACCINE Market Overview 11.3. Europe DENDRITIC CELL CANCER VACCINE Market Value Share Analysis, By Product Type 11.4. Europe DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 11.4.1. CreaVax 11.4.2. Sipuleucel-T (Provenge) 11.4.3. Others 11.5. Europe DENDRITIC CELL CANCER VACCINE Market Value Share Analysis, By End-user 11.6. Europe DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 11.6.1. Paediatrics 11.6.2. Adults 11.7. Europe DENDRITIC CELL CANCER VACCINE Market Value Share Analysis, By Country 11.8. Europe DENDRITIC CELL CANCER VACCINE Market Forecast, By Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Sweden 11.8.7. CIS countries 11.8.8. Rest of Europe 11.9. Germany DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 11.9.1. CreaVax 11.9.2. Sipuleucel-T (Provenge) 11.9.3. Others 11.10. Germany DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 11.10.1. Paediatrics 11.10.2. Adults 11.11. U.K. DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 11.11.1. CreaVax 11.11.2. Sipuleucel-T (Provenge) 11.11.3. Others 11.12. U.K. DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 11.12.1. Paediatrics 11.12.2. Adults 11.13. France DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 11.13.1. CreaVax 11.13.2. Sipuleucel-T (Provenge) 11.13.3. Others 11.14. France DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 11.14.1. Paediatrics 11.14.2. Adults 11.15. Italy DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 11.15.1. CreaVax 11.15.2. Sipuleucel-T (Provenge) 11.15.3. Others 11.16. Italy DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 11.16.1. Paediatrics 11.16.2. Adults 11.17. Spain DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 11.17.1. CreaVax 11.17.2. Sipuleucel-T (Provenge) 11.17.3. Others 11.18. Spain DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 11.18.1. Paediatrics 11.18.2. Adults 11.19. Sweden DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 11.19.1. CreaVax 11.19.2. Sipuleucel-T (Provenge) 11.19.3. Others 11.20. Sweden DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 11.20.1. Paediatrics 11.20.2. Adults 11.21. CIS countries DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 11.21.1. CreaVax 11.21.2. Sipuleucel-T (Provenge) 11.21.3. Others 11.22. CIS countries DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 11.22.1. Paediatrics 11.22.2. Adults 11.23. Rest of Europe DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 11.23.1. CreaVax 11.23.2. Sipuleucel-T (Provenge) 11.23.3. Others 11.24. Rest of Europe DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 11.24.1. Paediatrics 11.24.2. Adults 11.25. Europe DENDRITIC CELL CANCER VACCINE Market Attractiveness Analysis 11.25.1. By End-user 11.25.2. By Product Type 11.26. PEST Analysis 11.27. Key Trends 11.28. Key Developments 12. Asia Pacific DENDRITIC CELL CANCER VACCINE Market Analysis 12.1. Key Findings 12.2. Asia Pacific DENDRITIC CELL CANCER VACCINE Market Overview 12.3. Asia Pacific DENDRITIC CELL CANCER VACCINE Market Value Share Analysis, By Product Type 12.4. Asia Pacific DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 12.4.1. CreaVax 12.4.2. Sipuleucel-T (Provenge) 12.4.3. Others 12.5. Asia Pacific DENDRITIC CELL CANCER VACCINE Market Value Share Analysis, By End-user 12.6. Asia Pacific DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 12.6.1. Paediatrics 12.6.2. Adults 12.7. Asia Pacific DENDRITIC CELL CANCER VACCINE Market Value Share Analysis, By Country 12.8. Asia Pacific DENDRITIC CELL CANCER VACCINE Market Forecast, By Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. South Korea 12.8.5. Australia 12.8.6. ASEAN 12.8.7. Rest of Asia Pacific 12.9. Asia Pacific DENDRITIC CELL CANCER VACCINE Market Analysis, By Country 12.10. China DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 12.10.1. CreaVax 12.10.2. Sipuleucel-T (Provenge) 12.10.3. Others 12.11. China DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 12.11.1. Paediatrics 12.11.2. Adults 12.12. India DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 12.12.1. CreaVax 12.12.2. Sipuleucel-T (Provenge) 12.12.3. Others 12.13. India DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 12.13.1. Paediatrics 12.13.2. Adults 12.14. Japan DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 12.14.1. CreaVax 12.14.2. Sipuleucel-T (Provenge) 12.14.3. Others 12.15. Japan DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 12.15.1. Paediatrics 12.15.2. Adults 12.16. South Korea DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 12.16.1. CreaVax 12.16.2. Sipuleucel-T (Provenge) 12.16.3. Others 12.17. South Korea DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 12.17.1. Paediatrics 12.17.2. Adults 12.18. Australia DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 12.18.1. CreaVax 12.18.2. Sipuleucel-T (Provenge) 12.18.3. Others 12.19. Australia DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 12.19.1. Paediatrics 12.19.2. Adults 12.20. ASEAN DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 12.20.1. CreaVax 12.20.2. Sipuleucel-T (Provenge) 12.20.3. Others 12.21. ASEAN DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 12.21.1. Paediatrics 12.21.2. Adults 12.22. Rest of Asia Pacific DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 12.22.1. CreaVax 12.22.2. Sipuleucel-T (Provenge) 12.22.3. Others 12.23. Rest of Asia Pacific DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 12.23.1. Paediatrics 12.23.2. Adults 12.24. Asia Pacific DENDRITIC CELL CANCER VACCINE Market Attractiveness Analysis 12.24.1. By Product Type 12.24.2. By End-user 12.25. PEST Analysis 12.26. Key Trends 12.27. Key Developments 13. Middle East & Africa DENDRITIC CELL CANCER VACCINE Market Analysis 13.1. Key Findings 13.2. Middle East & Africa DENDRITIC CELL CANCER VACCINE Market Overview 13.3. Middle East & Africa DENDRITIC CELL CANCER VACCINE Market Value Share Analysis, By Product Type 13.4. Middle East & Africa DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 13.4.1. CreaVax 13.4.2. Sipuleucel-T (Provenge) 13.4.3. Others 13.5. Middle East & Africa DENDRITIC CELL CANCER VACCINE Market Value Share Analysis, By End-user 13.6. Middle East & Africa DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 13.6.1. Paediatrics 13.6.2. Adults 13.7. Middle East & Africa DENDRITIC CELL CANCER VACCINE Market Value Share Analysis, By Country 13.8. Middle East & Africa DENDRITIC CELL CANCER VACCINE Market Forecast, By Country 13.8.1. GCC Countries 13.8.2. South Africa 13.8.3. Nigeria 13.8.4. Egypt 13.8.5. Rest of Middle East & Africa 13.9. Middle East & Africa DENDRITIC CELL CANCER VACCINE Market Analysis, By Country 13.10. GCC Countries DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 13.10.1. CreaVax 13.10.2. Sipuleucel-T (Provenge) 13.10.3. Others 13.11. GCC Countries DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 13.11.1. Paediatrics 13.11.2. Adults 13.12. South Africa DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 13.12.1. CreaVax 13.12.2. Sipuleucel-T (Provenge) 13.12.3. Others 13.13. South Africa DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 13.13.1. Paediatrics 13.13.2. Adults 13.14. Nigeria DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 13.14.1. CreaVax 13.14.2. Sipuleucel-T (Provenge) 13.14.3. Others 13.15. Nigeria DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 13.15.1. Paediatrics 13.15.2. Adults 13.16. Egypt DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 13.16.1. CreaVax 13.16.2. Sipuleucel-T (Provenge) 13.16.3. Others 13.17. Egypt DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 13.17.1. Paediatrics 13.17.2. Adults 13.18. Rest of Middle East & Africa DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 13.18.1. CreaVax 13.18.2. Sipuleucel-T (Provenge) 13.18.3. Others 13.19. Rest of Middle East & Africa DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 13.19.1. Paediatrics 13.19.2. Adults 13.20. Middle East & Africa DENDRITIC CELL CANCER VACCINE Market Attractiveness Analysis 13.20.1. By Product Type 13.20.2. By End-user 13.21. PEST Analysis 13.22. Key Trends 13.23. Key Developments 14. South America DENDRITIC CELL CANCER VACCINE Market Analysis 14.1. Key Findings 14.2. South America DENDRITIC CELL CANCER VACCINE Market Overview 14.3. South America DENDRITIC CELL CANCER VACCINE Market Value Share Analysis, By Product Type 14.4. South America DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 14.4.1. CreaVax 14.4.2. Sipuleucel-T (Provenge) 14.4.3. Others 14.5. South America DENDRITIC CELL CANCER VACCINE Market Value Share Analysis, By End-user 14.6. South America DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 14.6.1. Paediatrics 14.6.2. Adults 14.7. South America DENDRITIC CELL CANCER VACCINE Market Value Share Analysis, By Country 14.8. South America DENDRITIC CELL CANCER VACCINE Market Forecast, By Country 14.8.1. Brazil 14.8.2. Colombia 14.8.3. Argentina 14.8.4. Rest of South America 14.9. South America DENDRITIC CELL CANCER VACCINE Market Analysis, By Country 14.10. Brazil DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 14.10.1. CreaVax 14.10.2. Sipuleucel-T (Provenge) 14.10.3. Others 14.11. Brazil DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 14.11.1. Paediatrics 14.11.2. Adults 14.12. Colombia DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 14.12.1. CreaVax 14.12.2. Sipuleucel-T (Provenge) 14.12.3. Others 14.13. Colombia DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 14.13.1. Paediatrics 14.13.2. Adults 14.14. Argentina DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 14.14.1. CreaVax 14.14.2. Sipuleucel-T (Provenge) 14.14.3. Others 14.15. Argentina DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 14.15.1. Paediatrics 14.15.2. Adults 14.16. Rest of South America DENDRITIC CELL CANCER VACCINE Market Forecast, By Product Type 14.16.1. CreaVax 14.16.2. Sipuleucel-T (Provenge) 14.16.3. Others 14.17. Rest of South America DENDRITIC CELL CANCER VACCINE Market Forecast, By End-user 14.17.1. Paediatrics 14.17.2. Adults 14.18. South America DENDRITIC CELL CANCER VACCINE Market Attractiveness Analysis 14.18.1. By Product Type 14.18.2. By End-user 14.19. PEST Analysis 14.20. Key Trends 14.21. Key Developments 15. Company Profiles 15.1. Market Share Analysis, By Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players By price, presence, market share, End-user, and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A By Regions, Investment and End-user 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. 3M Company 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Development Footprint 15.3.2. Batavia Bioservices 15.3.3. CiMaas 15.3.4. Activartis 15.3.5. Dendreon 15.3.6. Merck KGaA 15.3.7. GlaxoSmithKline plc 15.3.8. Northwest Bio therapeutics 15.3.9. Tella Incorporation 15.3.10. Creagene 15.3.11. Immunocellular Therapeutics 15.3.12. Medigene AG 15.3.13. HOOKPIA Pharma Inc 15.3.14. PDC Line Pharma 15.3.15. Kiromic 15.3.16. Immunicum 15.3.17. DCPrime 15.3.18. DanDrit Biotech 15.3.19. Elios Therapeutics 15.3.20. Bellicium Pharmaceuticals 15.3.21. SOTIO 15.3.22. Theravectys 15.3.23. Vaxil Bio therapeutics 15.3.24. Argos Therapeutics

About This Report

Report ID 81960
Category Healthcare
Published Date February 2021
Updated Date
Contact Us